Tim Colby
Tim Colby
Sep 8, 2018 · 2 min read

People must wonder how the massive, MIC, medical industrial complex component Pharma, will enter this process specifically. Indications are the same way big Pharma always looks after their profit wagon*, excuse me, profit tanker. Look at the blood thinner warfarin, tricky to administer by regular GPs as it must be monitored during usage. But it’s way off patent so any drug that can use the active parts of warfarin and add some patentable concoction is advertised, aka marketed, during high-ad-rate cost times like the national news shows. We have all seen this marketing, little vignettes where people look happy after taking some magic pill, that finally got some approval from the FDA, and then the tiny font disclaimers appear, the less visible screen printed script, (maybe gray on white?) accompanied with all the possible circumstances superpositioned over smiley people while a barely audible voice rattles off that screen text in some quick non-descript voiceover, which by the way could include a medical term known as ‘death’. Point is the new drug costs way more than the older active ingredient that worked but in warfarin’s case trickier to administer cause must be prescribed, unlike aspirin, and it always helps to circulate stories how one of the warfarin’s earlier uses was a rat poison additive. Even aspirin could be used to thin rat blood, but heck that's way off patent too.

If upcoming trials pan out for some future treatment, as the author suggests possible scenarios with further drug developments, also, IMO, watch what happens to the metformin clones and pill marketing, no doubt smiley faces and nice music and quiet disclaimers, while happy people dance around in the background, will appear all over the news hours. That’s just part of the way any drug treatments are handled in this country, another is making it as hard as possible to pick up much cheaper comparable working meds across USA borders north and south, gee, I wonder who would do such a thing? Duhh.

I guess what I’m saying is part of the whole disclaimer routine performed during drug marketing presentations is, an additional item to the disclaimers list, especially in USA, that is ‘marketing’.

*part of the process of getting new drugs through the regulatory process is some big entity trying to control every aspect of that process, including IMO, finding jobs for out of work regulators, buying congressional representatives, and I think you get the picture.

    Tim Colby

    Written by

    Tim Colby